ACA marketplace GLP-1 obesity coverage falls to 26 carriers for 2026

GLP-1 coverage for obesity is getting harder to find in Affordable Care Act marketplace plans. An analysis of the 300 carriers offering marketplace plans in 2026 found that 26 of them cover GLP-1 medications for treating obesity, and that such plans are available in only nine states ^[1].

The analysis was conducted with funding from the Robert Wood Johnson Foundation and shared with Becker's Payer Issues, which published the findings on December 2, 2025. It reviewed the policies of those 300 carriers for three GLP-1 drugs: Wegovy, Zepbound and Saxenda ^[1].

The number of people enrolled in marketplace plans that include GLP-1 coverage for weight loss fell from 3.6 million in 2024 to 2.8 million in 2026, according to the analysis ^[1]. If the same 24.5 million people who were enrolled in ACA plans in 2025 signed up again in 2026, less than 10 percent would have coverage for the drugs, and only a fraction of those would satisfy the stricter requirements the plans set for 2026, the analysis found ^[1].

The nine states with marketplace plans that cover GLP-1s for obesity are California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware and Georgia. In California and North Dakota, every carrier offers plans that cover the drugs ^[1].

Even where coverage exists, the conditions are narrow. Among carriers that cover GLP-1s for obesity, all but four limit coverage to people with severe obesity, defined as a body mass index of 40 or above, rather than the lower thresholds used in the drugs' approved labeling ^[1].

Every carrier that covers the drugs also requires documentation that the enrollee took part in a diet and exercise program for three to nine months before requesting a GLP-1, along with proof that the person was unable to lose weight ^[1].

Why it matters for patients

For adults who buy their own insurance on the ACA marketplaces, whether a GLP-1 for weight loss is covered depends heavily on where they live and which carrier they pick. In 41 states, the analysis found no marketplace carrier covering the drugs for obesity at all ^[1].

The BMI-40 requirement is a practical hurdle. People with a body mass index between 30 and 40 — the range where Wegovy and Zepbound are approved for weight management — would generally not qualify for coverage under these plans, even in the states and carriers that do offer it ^[1].

The diet-and-exercise documentation requirement adds a second hurdle, particularly for someone who is newly enrolled and may not have a record of a supervised program. The analysis describes prior participation and proof of unsuccessful weight loss as prerequisites for a coverage request ^[1].

Several things are not addressed in the analysis. It does not report what patients pay out of pocket when a plan does not cover a GLP-1, whether manufacturer savings programs change the picture, or how diabetes-related coverage for these drugs may differ from obesity coverage. The analysis covers plan year 2026 only; whether the trend continues in later years has not been reported ^[1].

Tirzepatide (sold as Mounjaro and Zepbound) and semaglutide (sold as Ozempic, Wegovy and Rybelsus) are the molecules most often discussed in this category. The analysis tracked coverage for Zepbound, Wegovy and Saxenda specifically ^[1].

For patients already taking one of these drugs through a marketplace plan, the analysis does not say whether existing coverage will continue, or how carriers will handle enrollees who no longer meet the 2026 requirements. Those details have not been disclosed ^[1].